Detalhe da pesquisa
1.
Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance.
Ann Hepatol
; 28(2): 100899, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36632975
2.
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Ann Intern Med
; 175(9): 1221-1229, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35939812
3.
Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.
J Viral Hepat
; 27(11): 1222-1233, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32594612
4.
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study.
Liver Int
; 40(5): 1042-1051, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31765046
5.
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.
J Viral Hepat
; 26(6): 675-684, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30739366
6.
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
J Viral Hepat
; 26(9): 1127-1138, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31108015
7.
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Hepatology
; 67(6): 2113-2126, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29473975
8.
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.
J Gastroenterol Hepatol
; 34(9): 1597-1603, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30779220
9.
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study.
J Gastroenterol Hepatol
; 34(1): 12-21, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30311701
10.
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
J Antimicrob Chemother
; 72(12): 3406-3413, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961714
11.
Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease.
Hepatol Res
; 47(12): 1340-1345, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28334495
12.
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Ann Intern Med
; 165(9): 625-634, 2016 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27537841
13.
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
Clin Infect Dis
; 62(1): 32-6, 2016 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26371152
14.
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
Ann Intern Med
; 163(1): 1-13, 2015 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25909356
15.
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.
J Hepatol
; 63(3): 564-72, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25895428
16.
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Gastroenterology
; 147(2): 366-76.e6, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24727022
17.
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.
PLoS Pathog
; 9(6): e1003404, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23818843
18.
Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.
Antimicrob Agents Chemother
; 58(7): 3610-7, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24733463
19.
Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
J Virol
; 86(4): 2239-50, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22156519
20.
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).
J Infect Dis
; 206(2): 258-66, 2012 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22561365